Aldactone – a modern drug, widely used in the fight against edema. Aldactone (Spironolactone) – is a potassium-preserving diuretic of prolonged action. The effect of treatment is shown on 3-5 days of admission.
Aldactone is prescribed for edema caused by:
- Chronic heart failure;
- Hepatic insufficiency, including cirrhosis;
- Nephrotic syndrome;
- Adrenal adrenal gland;
- Arterial hypertension.
To combat swelling Aldactone (Spironolactone) may be prescribed even to pregnant women. The method of application and dosage of the drug are determined by the doctor on the basis of clinical studies of the patient’s condition.
Has a diuretic, potassium-sparing, hypotensive effect. It inhibits the reabsorption of sodium ions through the apical membrane of the cells of the renal epithelium and increases urinary excretion of sodium, chlorine and water ions. Has a potassium-sparing effect: it inhibits aldosterone-regulated exchange of sodium ions on potassium ions, lowers the secretion and excretion of potassium, magnesium, urea and increases their concentration in the blood. Enhances excretion. Lowers the acidity of urine. Diuretic effect is manifested on the 2nd-5th day and persists for 2-3 days after discontinuation. Antihypertensive activity is caused by an increase in the excretion of sodium ions and a decrease in the volume of circulating blood and extracellular fluid; Manifested in the 2-3 nd week of treatment. Increases the activity of glucuronyltransferase, increases the amount of conjugated bilirubin in the urine, reduces the risk of arrhythmias. When ingested completely absorbed. Quickly and intensely biotransformiruetsya in the liver with the formation of several active metabolites. Almost completely binds to blood plasma proteins. It is excreted in urine, partially excreted with bile and feces.
Steroidal anti-inflammatory drugs and diuretics (benzothiadiazine derivatives, furosemide, ethacrynic acid, etc.) intensify and accelerate diuretic and natriuretic effects, ACE inhibitors (inhibit the release of aldosterone), indomethacin, cyclosporine, other potassium-sparing diuretics, potassium preparations (in Including potassium chloride) and potassium supplements – increase the risk of hyperkalemia (especially in the presence of kidney failure). Sympathomimetic drugs reduce antihypertensive properties, NSAIDs (indomethacin and acetylsalicylic acid) – diuretic, natriuretic and antihypertensive activity and increase the risk of developing renal failure. Potentiates the effect of diuretic and antihypertensive agents, increases the toxic effects of lithium preparations, hinders the development of hypokalemia in the appointment of furosemide and other diuretics that cause it, reduces the effect of cardiac glycosides, anticoagulants (coumarin derivatives, indanedione, heparin), vasoconstrictive action of adrenaline and inhibits antiulcer – carbenoksolona (Accelerates biotransformation and excretion).